Sequence Bio
Sequence Bio, headquartered in St. John's, Canada, is a healthcare company focused on drug discovery and delivery, utilizing the unique genetic diversity of Newfoundland to advance medical research.
Services
Sequence Bio provides services in drug discovery and delivery within the healthcare industry. They lead research initiatives like the Newfoundland and Labrador Genome Project, focusing on the genetic makeup of 10,000 volunteering participants. Their platform integrates systems biology and data-driven computation to identify true signals of disease. They collaborate with pharmaceutical and biotech companies to shorten research and development timelines through custom discovery cohorts. Ethical research underpins their operations, requiring approval from the Health Research Ethics Board (HREB).
Founders
Headquartered in St. John's, Newfoundland and Labrador, Sequence Bio was established with a mission to leverage the Newfoundland founder effect to discover better drug targets for life-changing medicines. The company leads extensive genomics research to fulfill this mission and has built a reputation for its pioneering work in this field.
Team
Sequence Bio has a team of 52 professionals. They emphasize the importance of a diverse workforce and maintain a respectful and inclusive workplace. The company offers a comprehensive benefits plan, a competitive stock option program, and professional development resources for employees, demonstrating their commitment to employee welfare and growth.
Industry
Operating within the healthcare industry, Sequence Bio specializes in the sub-industry of drug discovery and delivery. The company's work is nationally recognized, and it has been named one of Canada’s Top Small & Medium Employers. Sequence Bio is also a champion for improving diversity in STEM.
Y-Combinator Batch S19
Sequence Bio participated in the Y-Combinator batch S19. This prestigious startup accelerator provided the company with an invaluable boost to grow and refine their operations, allowing them to enhance their contributions to the drug discovery and delivery sectors.